To include your compound in the COVID-19 Resource Center, submit it here.

NICE does not recommend Novartis' Rydapt for AML

The U.K.'s NICE issued draft guidance recommending against the use of Rydapt midostaurin (CGP 41251, PKC412) from Novartis AG (NYSE:NVS; SIX:NOVN)

Read the full 211 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE